REVOLUTIONIZING RNAi
Switch Therapeutics is developing biomarker-gated, innovative genetic medicines to transform the treatment of central nervous system diseases.
Switch Therapeutics is developing biomarker-gated, innovative genetic medicines to transform the treatment of central nervous system diseases.
OUR SCIENCE
OUR PROPRIETARY CONDITIONALLY ACTIVATED siRNA (CASi) PLATFORM COMBINES ADVANTAGEOUS PROPERTIES OF SINGLE AND DOUBLE-STRANDED RNA IN A SINGLE MOLECULE, ALLOWING FOR EFFICIENT SELF-DELIVERY AND UPTAKE AS WELL AS POTENT AND DURABLE KNOCKDOWN. THE PLATFORM ALSO OFFERS THE UNPRECEDENTED ABILITY TO TARGET CELL TYPES AND CELL STATES, AN APPROACH THAT REVOLUTIONIZES THE ABILITY TO TREAT DEVASTATING DISEASES.
Switch’s Conditionally Activated siRNA (CASi) molecules combine the best attributes of antisense oligonucleotides (ASO) and siRNAs. Our technology can be applied to virtually any cell and/or tissue type for selective activation. Our initial focus is to develop our precision medicines for central nervous system (CNS) diseases with high unmet need.
Switch is building an extensive CNS pipeline enabled by CASi
THE CASi CONSTRUCT
EACH CASi MOLECULE CONSISTS OF A MODULAR SENSOR DOMAIN AND A PAYLOAD DOMAIN OF A SMALL INTERFERING RNA (siRNA). SENSOR DOMAIN MODULARITY WILL ENABLE US TO DELIVER OTHER RNA PAYLOADS IN THE FUTURE.
In addition to facilitating self-delivery and uptake, the CASi sensor strand creates expanded chemical and structural space, which allows multiple options for the attachment of targeting and biodistribution ligands.
The combination of a unique mechanism for effective self-delivery as well as cell selectivity enables new avenues for next generation RNAi therapy.
CASi molecules target RNAi activity to specific cell types with unique expression of sensor genes. By enabling cell-selective knockdown of targets by RNAi, CASi molecules have the ability to improve therapeutic windows for existing targets and open the door for numerous therapeutic applications.
About Us
We are an emerging precision neuroscience biotechnology company pioneering a new type of RNAi medicine with the goal of treating a range of CNS diseases.
![Image of the Golden Gate Bridge in San Francisco](https://www.switchthera.com/wp-content/uploads/2023/03/homepage-about-us-san-fransisco-bridge.png)
![Switch research associate Raquel Hernandez smiling while holding bottle and using lab equipment](https://www.switchthera.com/wp-content/uploads/2022/03/Homepage-Support-Image-1.png)
EXPLORE CAREER OPPORTUNITIES WITH SWITCH THERAPEUTICS
At Switch, we value an environment built on scientific values to promote innovation, collaboration and integrity within the organization. We are a dynamic, growing company endeavoring to tackle complex challenges together and develop innovative and effective medicines for the patients most in need.